Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Murine-Derived
  • Granulomatosis with Polyangiitis
  • Immunosuppressive Agents
  • Microscopic Polyangiitis
  • Remission Induction

abstract

  • Current treatment regimens are largely successful in controlling AAV, but in approximately one-fourth of patients, active disease persists or recurs in the first 6 months despite treatment. PR3-ANCA positivity is a risk factor for recurrence or persistence of severe disease. ANCA titers and B cell detectability are poor predictors of both disease relapse and disease quiescence in the first 6 months.

publication date

  • August 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4949954

Digital Object Identifier (DOI)

  • 10.1002/art.38044

PubMed ID

  • 23754238

Additional Document Info

start page

  • 2441

end page

  • 9

volume

  • 65

number

  • 9